Diamyd Medical AB (Stockholm NASDAQ, First North) is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression.
Patents Information here is NOT comprehensive as it depends on news items rather than patent database information extraction.
In 2026, Diamyd received notice that it would be granted a patent in Japan for antigenic treatment of Type I diabetes patients carrying the HLA DR4-DQ8 haplotype. In the United States, the firm received notice it would be granted a methodological patent for alum-based intralymphatic retogatein (one of the company's investigaional drugs) admnistration.
External links Diamyd Medical AB References